Sequencing and Combining Targeted Therapies in Melanoma
Omid Hamid, MD, discusses sequencing and combining targeted therapies in the treatment of melanoma.
Clinical Pearls
Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses sequencing and combining targeted therapies in the treatment of melanoma.
- Because of their ability to induce a rapid response and palliative benefit, targeted therapies should be used in patients with rapidly dividing disease, high tumor bulk, or poor performance status.
- Combining targeted therapies with immunotherapies is an appropriate way to achieve substantial progression-free survival benefit.
Recent Videos
Related Content
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025Article
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
